Skip to content
Insider tapeFilings through Fri, Oct 9
Watchlist
MGX

Metagenomi Therapeutics (MGX) stock: insider trades, news & valuation

Health Care · Net buying
Close · Oct 9, 2026 $1.00 +0.7% on the day -68.1% over 12 months 52-week range $0.98 – $3.35

Share price and insider trades

MGX closeInsider buyInsider sale
01234NovDecJan 2026FebMarAprMayJunJulAugSepOctSold $5,114 on 2026-09-08 · Jian Irish, Matthew Wein, Pamela WapnickSold $5,872 on 2026-03-05 · Jian Irish, Matthew Wein, Pamela WapnickSold $9,333 on 2026-06-05 · Jian Irish, Matthew Wein, Pamela WapnickSold $12,756 on 2025-12-05 · Brian C. Thomas, Jian Irish, Matthew Wein, Pamela WapnickBought $23,401 on 2026-09-09 · Laurence Reid
Bought, 12 months$23K
Sold, 12 months$44K
Insiders buying1
Insiders selling4

Metagenomi Therapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 1 insider bought $23K and 4 sold $44K of MGX stock on the open market.

MGX insider buying and selling by quarter

Open-market purchases (green, above the line) and sales (red, below), by trade date.

Q3 2025: $11K sold (4 trades)Q3 2025Q4 2025: $13K sold (4 trades)Q4 2025Q1 2026: $6K sold (3 trades)Q1 2026Q2 2026: $9K sold (3 trades)Q2 2026Q3 2026: $23K bought (2 trades)$23KQ3 2026: $5K sold (3 trades)Q3 2026Q4 2026
QuarterBoughtPurchasesSoldSales
Q4 2026—0—0
Q3 2026$23K2$5K3
Q2 2026—0$9K3
Q1 2026—0$6K3
Q4 2025—0$13K4
Q3 2025—0$11K4

Valuation, profit and volume

P/E (trailing)n/aSector median 24.7
Market value$37.8MBiotechnology
Profit margin0.0%Revenue growth —
Volume vs. 50-day1.5×Last 5 sessions
Insiders' paper profit−$3KOn all tracked purchases -14.5%

Summary

Over the past 12 months, 1 Metagenomi Therapeutics, Inc. insider reported open-market purchases totaling $23K, while 4 insiders reported sales totaling $44K. 0 of 17 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.

MGX stock news and SEC filings

Recent 8-K filings and headlines. Tone is scored from the headline wording; “Policy” marks regulatory, trade or government topics.

Insider transactions

Open-market purchases and sales.

Filed Insider Type Shares Price Value Since Score
Sep 11SEC Laurence ReidDirector Buy 19,883new position $1.17 $23K -14.5% —
Sep 11SEC Laurence ReidDirector Buy 11720,000 held (+1%) $1.18 $138 -15.3% —
Sep 10SEC Jian IrishSee Remarks Sell 2,140375,393 held (−1%) $1.16 $2K -13.8% —
Sep 10SEC Pamela WapnickCFO Sell 1,911206,580 held (−1%) $1.16 $2K -13.8% —
Sep 10SEC Matthew WeinSee Remarks Sell 358126,133 held (−0%) $1.16 $415 -13.8% —
Jun 10SEC Jian IrishSee Remarks Sell 3,737377,533 held (−1%) $1.30 $5K -23.1% —
Jun 10SEC Pamela WapnickCFO Sell 2,884208,491 held (−1%) $1.30 $4K -23.1% —
Jun 10SEC Matthew WeinSee Remarks Sell 558126,491 held (−0%) $1.30 $725 -23.1% —
Mar 9SEC Jian IrishCEO Sell 1,607333,770 held (−0%) $1.60 $3K -37.5% —
Mar 9SEC Pamela WapnickCFO Sell 1,581187,375 held (−1%) $1.60 $3K -37.5% —
Mar 9SEC Matthew WeinSee Remarks Sell 482114,549 held (−0%) $1.60 $771 -37.5% —
Dec 8SEC Brian C. ThomasDirector Sell 3,8302,510,960 held (−0%) $1.77 $7K -43.5% —
Dec 8SEC Jian IrishCEO Sell 1,602563,839 held (−0%) $1.77 $3K -43.5% —
Dec 8SEC Pamela WapnickCFO Sell 1,576188,956 held (−1%) $1.77 $3K -43.5% —
Dec 8SEC Matthew WeinSee Remarks Sell 199115,031 held (−0%) $1.77 $352 -43.5% —
Dec 1SEC Brian C. ThomasDirector Sell 2,7012,514,790 held (−0%) $1.81 $5K -44.8% —
Dec 1SEC Jian IrishCEO Sell 1,602316,941 held (−1%) $1.81 $3K -44.8% —
Dec 1SEC Pamela WapnickCFO Sell 1,57670,532 held (−2%) $1.81 $3K -44.8% —
Dec 1SEC Matthew WeinSee Remarks Sell 19919,230 held (−1%) $1.81 $360 -44.8% —

Insiders at Metagenomi Therapeutics, Inc.

InsiderBoughtSoldLast filingScore
Laurence ReidDirector $23K — Sep 11, 2026 —
Jian IrishSee Remarks — $16K Sep 10, 2026 —
Pamela WapnickCFO — $14K Sep 10, 2026 —
Brian C. ThomasDirector — $12K Dec 8, 2025 —
Matthew WeinSee Remarks — $3K Sep 10, 2026 —

Insider activity at other Health Care companies

Same sector, ranked by insider buying in the last 90 days.

  • SLBTSL Science Holding Ltd$10329.90B bought
  • KODKodiak Sciences Inc.$157M bought
  • ADRXADARx Pharmaceuticals, Inc.$87.7M bought
  • ATTOAttovia Therapeutics, Inc.$72.9M bought
  • MPLTMapLight Therapeutics, Inc.$65.5M bought
  • AVRAnteris Technologies Global Corp.$40.4M bought

MGX stock: common questions

Are Metagenomi Therapeutics, Inc. insiders buying MGX stock?

In the past 12 months, 1 insiders reported open-market purchases of MGX worth $23K. The latest was Director Laurence Reid bought $23K of MGX at $1.17 — first open-market purchase in our records; opens a new position.

Are Metagenomi Therapeutics, Inc. insiders selling MGX stock?

4 insiders reported sales worth $44K over the same period.

Where does this data come from?

Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.

What is MGX's 52-week range?

Over the past year MGX has traded between $0.98 and $3.35. It last closed at $1.00 on Oct 9, 2026.